Table 1 Baseline characteristics for the study cohort.
From: Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
Characteristics | N (%) |
|---|---|
Total number of patients | 101 (100%) |
 MGUS | 56 (55%) |
 SMM | 3 (3%) |
 MM | 39 (39%) |
 AL amyloidosis without coexisting MM | 3 (3%) |
Age at time of COVID-19 diagnosis, years | 70 (37–89) |
Female sex | 28 (28%) |
High risk FISH in patients with MM | 17/38 (45%) |
ISS stage in patients with MM | |
 Stage 1 | 10/37 (27%) |
 Stage 2 | 16/37 (43%) |
 Stage 3 | 11/37 (30%) |
Number of lines of treatment prior to COVID-19 diagnosis | |
 MGUS | 0 (0–1) |
 SMM | 0 |
 MM | 2 (0–13) |
AL amyloidosis | 3 (2–4) |
Anti-CD38 therapy within 6 months of the 1st COVID-19 diagnosis in MM/AL | 14/42 (33%) |
ASCT at any time prior to COVID-19 diagnosis in MM/AL | 25/42 (60%) |
ASCT within 6 months of COVID-19 diagnosis in MM/AL | 4/42 (10%) |
CAR-T cell therapy any time prior to COVID-19 diagnosis in MM | 2/39 (5%) |
CAR-T cell therapy within 6 months of COVID-19 diagnosis | 0 |
Immunoparesis within 3 months of COVID-19 diagnosis | 51/62 (82%) |
